Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P14868

UPID:
SYDC_HUMAN

ALTERNATIVE NAMES:
Aspartyl-tRNA synthetase; Cell proliferation-inducing gene 40 protein

ALTERNATIVE UPACC:
P14868; A8K3J2; D3DP77; Q2TNI3; Q32Q69; Q53HV4; Q53YC5; Q68CR9; Q9BW52

BACKGROUND:
The Aspartate--tRNA ligase, cytoplasmic, known alternatively as Aspartyl-tRNA synthetase, is pivotal in the aminoacylation of tRNA, facilitating the precise synthesis of proteins. This enzyme's activity ensures the correct assembly of amino acids into protein chains, critical for cellular function and health.

THERAPEUTIC SIGNIFICANCE:
Linked to a rare leukoencephalopathy characterized by spasticity and delayed motor development, the study of Aspartate--tRNA ligase, cytoplasmic offers a promising avenue for therapeutic intervention. Its involvement in such disorders underscores the potential for targeted treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.